Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser, and may not function properly. More information here...

    Results: 1 to 20 of 295

    1.

    Psychosocial and treatment correlates of opiate free success in a clinical review of a naltrexone implant program.

    Reece AS.

    Subst Abuse Treat Prev Policy. 2007 Nov 23;2:35.

    PMID:
    18036213
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    2.

    Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone.

    Hulse GK, Morris N, Arnold-Reed D, Tait RJ.

    Arch Gen Psychiatry. 2009 Oct;66(10):1108-15.

    PMID:
    19805701
    [PubMed - indexed for MEDLINE]
    Free Article
    4.

    Long-acting depot formulations of naltrexone for heroin dependence: a review.

    Krupitsky EM, Blokhina EA.

    Curr Opin Psychiatry. 2010 May;23(3):210-4. Review.

    PMID:
    20224403
    [PubMed - indexed for MEDLINE]
    5.

    Comparing drug-related hospital morbidity following heroin dependence treatment with methadone maintenance or naltrexone implantation.

    Ngo HT, Tait RJ, Hulse GK.

    Arch Gen Psychiatry. 2008 Apr;65(4):457-65.

    PMID:
    18391134
    [PubMed - indexed for MEDLINE]
    Free Article
    6.
    7.

    Achieving long-term continuous blood naltrexone and 6-beta-naltrexol coverage following sequential naltrexone implants.

    Hulse GK, Arnold-Reed DE, O'Neil G, Chan CT, Hansson RC.

    Addict Biol. 2004 Mar;9(1):67-72.

    PMID:
    15203441
    [PubMed - indexed for MEDLINE]
    8.

    Naltrexone and buprenorphine combination in the treatment of opioid dependence.

    Gerra G, Fantoma A, Zaimovic A.

    J Psychopharmacol. 2006 Nov;20(6):806-14. Epub 2006 Jan 9.

    PMID:
    16401652
    [PubMed - indexed for MEDLINE]
    9.

    Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial.

    Comer SD, Sullivan MA, Yu E, Rothenberg JL, Kleber HD, Kampman K, Dackis C, O'Brien CP.

    Arch Gen Psychiatry. 2006 Feb;63(2):210-8.

    PMID:
    16461865
    [PubMed - indexed for MEDLINE]
    Free Article
    10.

    A pilot study to assess the impact of naltrexone implant on accidental opiate overdose in 'high-risk' adolescent heroin users.

    Hulse GK, Tait RJ.

    Addict Biol. 2003 Sep;8(3):337-42.

    PMID:
    13129836
    [PubMed - indexed for MEDLINE]
    11.

    Blood naltrexone and 6-beta-naltrexol levels following naltrexone implant: comparing two naltrexone implants.

    Hulse GK, Arnold-Reed DE, O'Neil G, Chan CT, Hansson R, O'Neil P.

    Addict Biol. 2004 Mar;9(1):59-65.

    PMID:
    15203440
    [PubMed - indexed for MEDLINE]
    12.

    Mental health outcomes following naltrexone implant treatment for heroin-dependence.

    Ngo HT, Tait RJ, Arnold-Reed DE, Hulse GK.

    Prog Neuropsychopharmacol Biol Psychiatry. 2007 Apr 13;31(3):605-12. Epub 2007 Jan 16.

    PMID:
    17229510
    [PubMed - indexed for MEDLINE]
    13.

    Maintenance treatment with depot opioid antagonists in subcutaneous implants: an alternative in the treatment of opioid dependence.

    Carreño JE, Alvarez CE, Narciso GI, Bascarán MT, Díaz M, Bobes J.

    Addict Biol. 2003 Dec;8(4):429-38.

    PMID:
    14690879
    [PubMed - indexed for MEDLINE]
    14.

    Blood naltrexone levels over time following naltrexone implant.

    Ngo HT, Arnold-Reed DE, Hansson RC, Tait RJ, Hulse GK.

    Prog Neuropsychopharmacol Biol Psychiatry. 2008 Jan 1;32(1):23-8. Epub 2007 Jun 19.

    PMID:
    17651881
    [PubMed - indexed for MEDLINE]
    15.

    A new approach to preventing relapse in opiate addicts: a psychometric evaluation.

    Grüsser SM, Thalemann CN, Platz W, Gölz J, Partecke G.

    Biol Psychol. 2006 Mar;71(3):231-5. Epub 2005 Jul 19.

    PMID:
    16046046
    [PubMed - indexed for MEDLINE]
    16.

    Depot naltrexone: antagonism of the reinforcing, subjective, and physiological effects of heroin.

    Sullivan MA, Vosburg SK, Comer SD.

    Psychopharmacology (Berl). 2006 Nov;189(1):37-46. Epub 2006 Sep 14.

    PMID:
    16972105
    [PubMed - indexed for MEDLINE]
    17.

    Risk factors for craving and relapse in heroin users treated with oral or implant naltrexone.

    Hulse GK, Ngo HT, Tait RJ.

    Biol Psychiatry. 2010 Aug 1;68(3):296-302. Epub 2010 May 26.

    PMID:
    20537615
    [PubMed - indexed for MEDLINE]
    18.

    Rapid opiate detoxication in outpatient treatment: relationship with naltrexone compliance.

    Gerra G, Zaimovic A, Rustichelli P, Fontanesi B, Zambelli U, Timpano M, Bocchi C, Delsignore R.

    J Subst Abuse Treat. 2000 Mar;18(2):185-91.

    PMID:
    10716102
    [PubMed - indexed for MEDLINE]
    19.

    Clonidine and opiate receptor antagonists in the treatment of heroin addiction.

    Gerra G, Marcato A, Caccavari R, Fontanesi B, Delsignore R, Fertonani G, Avanzini P, Rustichelli P, Passeri M.

    J Subst Abuse Treat. 1995 Jan-Feb;12(1):35-41.

    PMID:
    7752296
    [PubMed - indexed for MEDLINE]
    20.

    Comparative treatment and mortality correlates and adverse event profile of implant naltrexone and sublingual buprenorphine.

    Reece AS.

    J Subst Abuse Treat. 2009 Oct;37(3):256-65. Epub 2009 Apr 25.

    PMID:
    19394789
    [PubMed - indexed for MEDLINE]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk